U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07091006) titled 'Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML' on July 07.
Brief Summary: Allogeneic hematopoietic cell transplantation (allo-HCT) is the only treatment that offers a possible cure for relapsed/refractory AML. Currently, the optimal preallo-HCT bridging regimen for relapsed/refractory AML patients is unclear. Venetoclax-based regimens, including Venetoclax + demethylating agents (HMA) , Venetoclax + HMA + other drugs and Venetoclax-based multidrug combinations as a bridging regimen improves response rate and post-transplant survival in relapsed/refractory AML patients. Therefore, the investi...